Jonathan Joseph Chipman | Spencer Fox Eccles School of Medicine

Jonathan Joseph Chipman | Spencer Fox Eccles School of Medicine
Jonathan Joseph Chipman, PhD
Languages spoken:
Portuguese, English
Academic Information
Departments
Adjunct -

Family & Preventive Medicine
, Primary -

Population Health Sciences
Lab
Lab Website: Chipman Lab
Visit Dr. Chipman's Lab Site
I am an Assistant Professor of Biostatistics within the Department of Population Health Sciences (since 2019), and serve as a member of the Cancer Biostatistics Shared Resource at the Huntsman Cancer Institute (HCI).
My academic journey began at
Brigham Young University
(BS, Statistical Science) and the
University of Minnesota
(MS, Biostatistics). I worked four years as an MS statistician at the
Dana-Farber Cancer Institute
under Drs.
Giovanni Parmigiani
(prediction risk modelling for the BRCA gene; BRCAPRO) and
Meredith Regan
(prostate screening and quality of life outcomes with
Dr. Martin Sanda
).
I earned my Ph.D. in
Biostatistics at Vanderbilt University
under
Dr. Robert Greevy
, gaining methodological expertise in designing randomized trials and collaborative expertise in analyzing small- and large-scale observational studies. I love the causal inference connection between randomized and non-randomized trials and considering the issues to causal inference that can arise.
In randomized trials, I advocate for adjusting randomization for covariates and using analytic strategies which carry as few modelling assumptions as possible. (Example:
Rematching on-the-Fly: Sequential Matched Randomization and a Case for Covariate-Adjusted Randomization
My scientific philosophy is open to Frequentist, Bayesian, Likelihood, or other inferential approaches though with attention to scientific relevance. That is, I value interval estimation and anchoring estimates on clinical context. (Example:
Sequential monitoring using the Second Generation P-Value with Type I error controlled by monitoring frequency
I married Danielle Duffy Chipman the month before joining the University of Utah. We have a son, Peter, who is playful and seems to share his dad’s love for sports and his parents love of music and the outdoors.
Research Statement
I am trained in the design and analysis of clinical trials and observational studies.
My students and I develop methods that increase a study’s efficiency and effectiveness. Our current emphasis is in developing covariate-adjusted randomization and sample-size adaptive monitoring methods.
These methods reduce on average the noise in estimating an effect, improve the ability to study key subgroups, and allow for following studies until drawing clinically meaningful conclusions regarding the strength of the true effect.
Education History
Undergraduate
Brigham Young University
BS
Graduate Training
University of Minnesota
MS
Doctoral Training
Vanderbilt University
PhD
Selected Publications
Journal Article
Biswas S, Atienza P,
Chipman J
, Hughes K, Barrera AM, Amos CI, Arun B, Parmigiani G (2013). Simplifying clinical use of the genetic risk prediction model BRCAPRO.
Breast Cancer Res Treat
139
(2), 571-9.
Chipman J
, Drohan B, Blackford A, Parmigiani G, Hughes K, Bosinoff P (2013). Providing access to risk prediction tools via the HL7 XML-formatted risk web service.
Breast Cancer Res Treat
140
(1), 187-93.
Biswas S, Atienza P,
Chipman J
, Blackford AL, Arun B, Hughes K, Parmigiani G (2016). A two-stage approach to genetic risk assessment in primary care.
Breast Cancer Res Treat
155
(2), 375-83.
Mazzola E,
Chipman J
, Cheng SC, Parmigiani G (2014). Recent BRCAPRO upgrades significantly improve calibration.
Cancer Epidemiol Biomarkers Prev
23
(8), 1689-95.
Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH, Nichols RC, Mendenhall WM, Williams CR, Regan MM,
Chipman JJ
, Crociani CM, Sandler HM, Sanda MG, Hamstra DA (2014). Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.
Cancer
120
(7), 1076-82.
Min JY, Griffin MR,
Chipman J
, Hackstadt AJ, Greevy RA, Grijalva CG, Hung AM, Roumie CL (2019). Recent metformin adherence and the risk of hypoglycaemia in the year following intensification with a sulfonylurea.
Diabet Med
36
(4), 482-490.
Chu PY, Hackstadt AJ,
Chipman J
, Griffin MR, Hung AM, Greevy RA Jr, Grijalva CG, Elasy T, Roumie CL (2020). Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
Diabetes Care
43
(7), 1462-1470.
Swami U, Isaacsson Velho P, Nussenzveig R,
Chipman J
, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.
Eur Urol
78
(5), 652-656.
Casper AC, Parsons MW,
Chipman J
, Burt LM Jr, Suneja G, Maurer KA, Gaffney DK (2021). Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
Gynecol Oncol
162
(2), 454-460.
Kishi T,
Chipman J
, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, Centola M, Miller FW, Rider LG (2020). Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis.
J Rheumatol
47
(7), 1011-1018.
Chang P, Szymanski KM, Dunn RL,
Chipman JJ
, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG (2011). Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.
J Urol
186
(3), 865-72.
Chipman JJ
, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, Regan MM, Chang P (2014). Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice.
J Urol
191
(3), 638-45.
Mihalcik S,
Chipman J
, Sanda M, Kaplan I, Crociani C, Chang P, PROST-QA Consortium (2016). Predicting erectile function following radiation therapy for prostate cancer at the point of care.
J Urol
195
(4), e150.
Roumie CL,
Chipman J
, Min JY, Hackstadt AJ, Hung AM, Greevy RA Jr, Grijalva CG, Elasy T, Griffin MR (2019). Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.
JAMA
322
, 1-11.
Pencina MJ,
Chipman J
, Steyerberg EW, Braun D, Fine JP, D'Agostino RB Sr (2017). Authors' response to comments.
Stat Med
36
(28), 4511-4513.
Chipman J
, Braun D (2017). Simpson's paradox in the integrated discrimination improvement.
Stat Med
36
(28), 4468-4481.
Presley CA,
Chipman J
, Min JY, Grijalva CG, Greevy RA, Griffin MR, Roumie CL (2019). Evaluation of Frailty as an Unmeasured Confounder in Observational Studies of Antidiabetic Medications.
J Gerontol A Biol Sci Med Sci
74
(8), 1282-1288.
Kazer MW, Bailey DE Jr,
Chipman J
, Psutka SP, Hardy J, Hembroff L, Regan M, Dunn RL, Crociani C, Sanda MG (2013). Uncertainty and perception of danger among patients undergoing treatment for prostate cancer.
BJU Int
111
(3 Pt B), E84-91.
Bigler ED, Abildskov TJ, Petrie JA, Johnson M, Lange N,
Chipman J
, Lu J, McMahon W, Lainhart JE (2010). Volumetric and voxel-based morphometry findings in autism subjects with and without macrocephaly.
Dev Neuropsychol
35
(3), 278-95.
Min JY, Hackstadt AJ, Griffin MR, Greevy RA Jr,
Chipman J
, Grijalva CG, Hung AM, Roumie CL (2019). Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death.
Diabetes Obes Metab
21
(12), 2626-2634.
Berger VW, Bour LJ, Carter K,
Chipman JJ
, Everett CC, Heussen N, Hewitt C, Hilgers RD, Luo YA, Renteria J, Ryeznik Y, Sverdlov O, Uschner D, Randomization Innovative Design Scientific Working Group. (2021). A roadmap to using randomization in clinical trials.
BMC Med Res Methodol
21
(1), 168.
Min JY, Presley CA, Wharton J, Griffin MR, Greevy RA Jr, Hung AM,
Chipman J
, Grijalva CG, Hackstadt AJ, Roumie CL (2019). Accuracy of a composite event definition for hypoglycemia.
Pharmacoepidemiol Drug Saf
28
(5), 625-631.
Vicier C, Werner L,
Chipman J
, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ (2019). Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.
Clin Genitourin Cancer
17
(1), 32-37.
Coletta AM, Playdon MC, Baron KG, Wei M, Kelley K, Vaklavas C, Beck A, Buys SS,
Chipman J
, Ulrich CM, Walker D, White S, Oza S, Zingg RW, Hansen PA (2021). The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors.
PLoS One
16
(10), e0258135.
Mihalcik SA,
Chipman JJ
, Sanda MG, Regan MM, Kaplan ID, Wagner AA, Crociani CM, Chang P, PROST-QA Consortium. (2018). Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP.
Pract Radiat Oncol
(6), 445-451.
Presley CA, Min JY,
Chipman J
, Greevy RA, Grijalva CG, Griffin MR, Roumie CL (2018). Validation of an algorithm to identify heart failure hospitalisations in patients with diabetes within the veterans health administration.
BMJ Open
(3), e020455.
Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J,
Chipman J
, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT, and the EDRN-PCA3 Study Group., Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S (2017). Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
JAMA Oncol
(8), 1085-1093.
Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen (2022). Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups.
Clinical genitourinary cancer
20
(3), e233-e243.
Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel (2022). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern.
JTO clinical and research reports
(3), 100280.
Wu YP, Parsons B, Jo Y, Chipman J, Haaland B, Nagelhout ES, Carrington J, Wankier AP, Brady H, Grossman (2022). Outdoor activities and sunburn among urban and rural families in a Western region of the US: Implications for skin cancer prevention.
Preventive medicine reports
29
, 101914.
Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney D (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy.
Advances in radiation oncology
(6), 101035.
Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata P (2022). Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race.
The oncologist
27
(10), e815-e818.
Chipman JJ, Mayberry L, Greevy RA J (2023). Rematching on-the-fly: Sequential matched randomization and a case for covariate-adjusted randomization.
Statistics in medicine
42
(22), 3981-3995.
Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney D (2023). Secondary malignancies in non-Hodgkin lymphoma survivors: 40¿years of follow-up assessed by treatment modality.
Cancer medicine
12
(3), 2624-2636.
Stump TK, Fastner S, Jo Y, Chipman J, Haaland B, Nagelhout ES, Wankier AP, Lensink R, Zhu A, Parsons B, Grossman D, Wu Y (2023). Objectively-Assessed Ultraviolet Radiation Exposure and Sunburn Occurrence.
International journal of environmental research and public health
20
(7),
Stump TK, Wetter DW, Kuzmenko T, Orleans B, Kolp L, Wirth J, Del Fiol G, Chipman J, Haaland B, Kaphingst KA, Hersh AL, Wu Y (2023). Preliminary Reach of an Information Technology Approach to Support COVID-19 Testing in Schools.
Pediatrics
152
(Suppl 1),
Lange SM, Vehawn J, Choudry MM, Ambrose JP, Cluff CM, Haaland BA, Paudel N, Chipman J, Hanson HA, O'Neil B (2023). Low-Value Prostate Cancer Screening Among Young Men With Private Insurance.
Urology practice
, 101097UPJ0000000000000461.
Dindinger-Hill K, Horns J, Ambrose J, Vehawn J, Choudry M, Hunt TC, Chipman J, Haaland B, Li J, Hanson HA, O'Neil (2024). Effect of Health Service Area on Primary Care Physician Provision of Low-Value Cancer Screening.
Annals of internal medicine
177
(5), 583-591.
Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal (2024). Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
BMC cancer
24
(1), 493.
Choudry M, Dindinger-Hill K, Ambrose J, Horns J, Vehawn J, Gill H, Murray NZ, Hunt TC, Martin C, Haaland B, Chipman J, Hanson HA, O'Neil B (2024). Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients.
Cancer medicine
13
(5), e7058.
Del Fiol G,Orleans B,Kuzmenko TV,Chipman J,Greene T,Martinez A,Wirth J,Meads R,Kaphingst KK,Gibson B,Kawamoto K,King AJ,Siaperas T,Hughes S,Pruhs A,Pariera Dinkins C,Lam CY,Pierce JH,Benson R,Borsato EP,Cornia R,Stevens L,Bradshaw RL,Schlechter CR,Wetter D (2024). SCALE-UP II: protocol for a pragmatic randomised trial examining population health management interventions to increase the uptake of at-home COVID-19 testing in community health centres.
BMJ open
14
(3),
Chipman JJ,Greevy RA,Mayberry LS,Blume J (2024). Sequential Monitoring Using the Second Generation P-Value with Type I Error Controlled by Monitoring Frequency.
The American statistician
Uschner D,Sverdlov O,Carter K,Chipman J,Kuznetsova O,Renteria J,Lane A,Barker C,Geller N,Proschan M,Posch M,Tarima S,Bretz F,Rosenberger W (2023). Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions.
Statistics in biopharmaceutical research
Carter K,Scheffold AL,Renteria J,Berger VW,Luo YA,Chipman JJ,Sverdlov (2023). Regulatory Guidance on Randomization and the Use of Randomization Tests in Clinical Trials: A Systematic Review.
Statistics in biopharmaceutical research
Sverdlov O,Carter K,Hilgers RD,Everett CC,Berger VW,Luo YA,Chipman JJ,Ryeznik Y,Ross J,Knight R,Yamada (2023). Which Randomization Methods Are Used Most Frequently in Clinical Trials? Results of a Survey by the Randomization Working Group.
Statistics in biopharmaceutical research
Einstein D,Patil D,Chipman J,Regan M,Davis K,Crociani C,Wagner A,Sanda M,Chang (2019). Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.
Urology
127
, 53-60.
Schlechter CR, Kuzmenko TV, Orleans B, Wirth J, Kaphingst KA, Gibson B, Kawamoto K, Siaperas T, Pruhs A, Dinkins CP, Greene T, Zhang Y, Chipman JJ, Friedrichs M, Lam CY, Pierce JH, Borsato EP, Cornia RC, Stevens L, Martinez A, Bradshaw RL, Hess R, Fiol GD, Wetter D (2024). Reach and Engagement With Population Health Management Interventions to Address COVID-19 Among Safety-Net Health Care Systems.
American journal of public health
114
(11), 1207-1211.
Wu YP, Brady HL, Wankier AP, Tanguy WJ, Smith HJ, Brunsgaard EK, Chipman J, DeSantis S, Abildso C, Haaland B, Schlechter CR, Wetter DW, Tercyak K (2024). Preliminary effects of a rural skin cancer prevention intervention for youths.
Health psychology
43
(5), 339-351.
Chipman JJ, Rosenberger WF, Sverdlov O, Uschner (2024). Special Issue on Randomization Methods to Design and Analyze Trial Estimands, Adjust for Covariates, and Implement Efficient Designs.
Statistics in Biopharmaceutical Research
16
(4), 403--404.
Jo Y, Puri S, Haaland B, Coletta AM, Chipman JJ, Embrey K, Kerrigan KC, Patel SB, Moynahan K, Gumbleton M, Akerley W (2025). Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer.
Clinical lung cancer
26
(1), 29-38.
Jo Y, Chipman JJ, Haaland B, Greene T, Kohli (2024). Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer.
JCO precision oncology
, e2400399.
Simon LH, Saviers-Steiger C, Dunston ER, Galyean P, Kimball ER, Mendez J, Zickmund SL, Hansen PA, Ulrich CM, LaStayo PC, Steinberg D, Noren CS, Finch A, Seckinger L, Braun E, Chipman J, Brownson KE, Oza S, Coletta A (2025). Feasibility and acceptability of the Comprehensive Oncology Rehabilitation and Exercise (CORE) clinical workflow algorithm in patients with newly diagnosed stage I-III breast cancer who undergo surgery as first-line treatment.
Cancer
131
(9), e35798.
Del Fiol G, Kuzmenko TV, Orleans B, Chipman JJ, Greene T, Meads R, Kaphingst KA, Gibson B, Kawamoto K, King AJ, Siaperas T, Hughes S, Pruhs A, Dinkins CP, Lam CY, Pierce JH, Benson R, Borsato EP, Cornia RC, Stevens L, Bradshaw RL, Schlechter CR, Wetter D (2025). Population-Based Digital Health Interventions to Deliver at-Home COVID-19 Testing: SCALE-UP II Randomized Clinical Trial.
Journal of medical Internet research
27
, e74145.
Sanuade O, Carroll A, Watson R, Ye J, Hill J, Chipman J, Wilson FA, King AJ, Kho A, Del Fiol G, Paris D, Smith J (2025). Contextual factors and implementation strategies for a multi-level community-based sodium reduction intervention in Chicago’s South Side: a qualitative study.
International Journal of Behavioral Nutrition and Physical Activity
22
(1), 93.
Tanguy WJ, Tercyak KP, Xu Y, Chipman J, Shen N, Joung C, Brady HL, Sleiman Jr MM, Grossman D, Theilen LH, Wu Y (2024). Reducing UVR exposure in pregnant women and infants: a pilot study.
Journal of Cancer Education
40
(4), 528--541.
Tay D, Dubose K, Chipman J, Ellington L, Alnajar M, Iacob E, Stephens C, Ornstein K (2025). Risk of mental health conditions in bereavement: a population-based analysis of lung cancer spouses.
Frontiers in Public Health
13
, 1539180.
Uschner D, Sverdlov O, Carter K, Chipman JJ, Kuznetsova O, Renteria J, Lane A, Barker C, Geller NL, Proschan M, Tarima S, Bretz F, Rosenberger W (2024). The Rejoinder.
Statistics in Biopharmaceutical Research
16
(4), 425--427.
Chipman J; Sverdlov O; Uschner Randomization Restrictions: Their Impact on Type I Error When Experimenting with Finite Populations.
Biometrics
Son, CH and Kim-Wang, SY and Sohn, JJ and Al-Hallaq, HA and Cursio, J and McCall, AR and Malik, R and Golden, DW and Kurnit, K and Chipman, J and other (2025). Multi-Institutional Phase I Results from RT-PACE: Phase I/II Study of Adjuvant Whole Pelvic Hypofractionated Radiotherapy for Non-Metastatic Cervical and Endometrial Cancer.
International Journal of Radiation Oncology, Biology, Physics
123
(1), S185--S186.
Wei, Jiawei and Mozumder, Sarwar I and Li, Liming and Xi, Dong and Xu, Jiajun and Lin, Ray and Sverdlov, Oleksandr and Chipman, Jonathan (2025). Current practice on covariate adjustment and stratified analysis—based on survey results by ASA oncology estimand working group conditional and marginal effect task force.
BMC Medical Research Methodology
25
(1), 1--10.
Wu, Yelena P and Chipman, Jonathan J and Kolp, Leighann and Stump, Tammy K and Kuzmenko, Tatyana V and Del Fiol, Guilherme and Haaland, Benjamin and Kaphingst, Kimberly A and Brooks, Roger and Hersh, Adam L and other (2025). Mobile Intervention for Increasing COVID-19 Testing in K-12 Schools Serving Disadvantaged Communities: Randomized Controlled Trial of SCALE-UP Counts.
Journal of Medical Internet Research
27
, e79775.
Review
Dunston ER, Mulibea PB, Chipman J, Zickmund S, Oza S, Zingg RW, Hansen PA, Coletta A (2022). Factors influencing engagement in hospital-based exercise oncology programs: A narrative review.
PM & R
15
(7), 916-924.
Book Chapter
Chipman J
(2017). Restricted Randomization: Pros and Cautions. In Berger VW (Ed.),
Randomization, Masking, and Allocation Concealment
(pp. 51-60). CRC Press.
Other
Yoshida, K and Bartel, A and Chipman, JJ and other (2020). tableone: Create ‘Table 1’ to Describe Baseline Characteristics. R package version 0.12. 0. 2020.